Posttransplant soluble CD30 as a predictor of acute renal allograft rejection

Experimental and Clinical Transplantation

Volumn 7, Issue 4, 2009, Pages 237-240

  Kamali, Koosha ^a   Abbasi, Mohammad Amin ^a   Farokhi, Babak ^b   Abbasi, Ata ^c   Fallah, Parvane ^a   Seifee, Mohammad Hasan ^a   Ghadimi, Naime ^a   Rezaie, Alireza R ^d  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Delayed graft function; Graft loss; Soluble CD30

Indexed keywords

CD30 ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY ALLOGRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD;

ACUTE DISEASE; ADULT; ANTIGENS, CD30; BIOLOGICAL MARKERS; DELAYED GRAFT FUNCTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 75649111978     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Truong DQ, Darwish AA, Gras J, et al. Immunological monitoring after organ transplantation: potential role of soluble CD30 blood level measurement. Transpl Immunol. 2007;17(4):283-287.
2. Cinti P, Pretagostini R, Arpino A, et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation. 2005;79(9):1154-1156.
3. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65-67.
4. Del Prete G, De Carli M, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J. 1995;9(1):81-86.
5. Romagnani S, Del Prete G, Maggi E, Chilosi M, Caligaris-Cappio F, Pizzolo G. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol. 1995;57(5):726-730. Review. Erratum in: J Leukoc Biol. 1995;57(6):978.
6. Süsal C, Pelzl S, Simon T, Opelz G. Advances in pre- and posttransplant immunologic testing in kidney transplantation. Transplant Proc. 2004;36(1):29-34.
7. Süsal C, Pelzl S, Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation. 2003;76(8):1231-1232.
8. Dong W, Shunliang Y, Weizhen W, et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol. 2006;16(1):41-45.
9. Pelzl S, Opelz G, Daniel V, Wiesel M, Süsal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation. 2003;75(3):421-423.
10. Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B Identification of patients at risk of acute rejection by pretransplantation and post-transplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation. 2006;81:1216-1219.
11. Ayed K, Abdallah TB, Bardi R, Abderrahim E, Kheder A. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection. Transplant Proc. 2006;38(7):2300-2302.
12. Giannoli C, Bonnet MC, Perrat G, et al. High pretransplantation soluble CD30 levels: impact in renal transplantation. Transplant Proc. 2007;39(8):2574-2575.
13. Slavcev A, Lácha J, Honsová E, et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol. 2005;14(2):117-121.
14. Weimer R, Süsal C, Yildiz S, et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant. 2006;6(8):1865-1874.
15. Altermann W, Schlaf G, Rothhoff A, Seliger B. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection? Nephrol Dial Transplant. 2007;22(10):2795-2799.